Condition: Dystrophic Epidermolysis Bullosa · DEB - Dystrophic Epidermolysis Bullosa · Recessive Dystrophic Epidermolysis Bullosa · Sponsor: Krystal Biotech, Inc.
KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
This description comes directly from the study's public registry record.
David Sweet, MD, PhD · 412-586-5830 · dsweet@krystalbio.com
Brittani Agostini, RN, CCRC · 412-586-5830 · bagostini@krystalbio.com
Always discuss trial participation with your own doctor first.
| Mission Dermatology Center | Rancho Santa Margarita, California, United States | Recruiting |
| Skin Research Institute | Coral Gables, Florida, United States | Recruiting |
| UMass Memorial Medical Center | Worcester, Massachusetts, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Texas Dermatology and Laser Specialists | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07016750